AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16967401 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard nursing care only
Number of subjects: 60
Study 14749208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) ingestion to suppress adipose tissue lipolysis
Number of subjects: 7
Study 14749208 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) without nicotinic acid ingestion
Number of subjects: 7
Study 11203912 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline, salt‐containing toothpaste
Number of subjects: 115
Study 11203912 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothgel of similar contents
Number of subjects: 115
Study 11203912 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothpaste
Number of subjects: 115
Study 9071101 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Number of subjects: 90
Study 9071101 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.2 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Number of subjects: 90
Study 9071101 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Number of subjects: 90
Study 8347901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention at clinic A
Number of subjects: 0
Study 8347901 — intervention group
Group type: COMPARATOR
Intervention: No pharmacist intervention at clinic B
Number of subjects: 0
Study 2939943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) 300 mg three times daily
Number of subjects: 129
Study 2939943 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg twice daily
Number of subjects: 129
Study 2939943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA)
Number of subjects: 129
Study 2939943 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 129
Study 2939943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) after cross-over
Number of subjects: 129
Study 2939943 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) after cross-over
Number of subjects: 129
Study 31391104 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus warm needling therapy (treatment group)
Number of subjects: 80
Study 31391104 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 80
Study 27774726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiix-prothrombin time (Fiix-PT)
Number of subjects: 66
Study 27774726 — intervention group
Group type: COMPARATOR
Intervention: PT-prothrombin time (PT)
Number of subjects: 66
Study 27774726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiix-INR
Number of subjects: 66
Study 27774726 — intervention group
Group type: COMPARATOR
Intervention: PT-INR
Number of subjects: 66
Study 27774726 — intervention group
Group type: EXPERIMENTAL
Intervention: FII and FX activity
Number of subjects: 66
Study 27774726 — intervention group
Group type: EXPERIMENTAL
Intervention: FII and FX
Number of subjects: 66
Study 27774726 — intervention group
Group type: EXPERIMENTAL
Intervention: FVII
Number of subjects: 66
Study 26409399 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, progressive, physiologically based, nurse-supervised, in-home exercise program (24 sessions over 12 weeks) targeting flexibility, strength, balance, endurance, and upper-limb function.
Number of subjects: 134
Study 26409399 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 134
Study 22382203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (CJ) - double-strength Ocean Spray light CJ (2 × 230 ml) daily for 4 months
Number of subjects: 84
Study 22382203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 21457292 — intervention group
Group type: COMPARATOR
Intervention: Care relationship mutuality
Number of subjects: 91
Study 18516002 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI group (pantoprazole 40 mg IV for 3 days, then 40 mg oral for 11 days)
Number of subjects: 47
Study 18516002 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous and oral placebo)
Number of subjects: 47
Study 16242376 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of hypertonic saline into the lumbar multifidus muscle
Number of subjects: 15
Study 16242376 — intervention group
Group type: COMPARATOR
Intervention: Comparison with pain maps from L4 medial dorsal rami and L4-5 interspinous ligaments
Number of subjects: 15
Study 12709008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% cream
Number of subjects: 30
Study 12709008 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin whitening complex 5% cream
Number of subjects: 30
Study 12709008 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30
Study 10906303 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment of small AAAs
Number of subjects: 127
Study 10906303 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for AAAs
Number of subjects: 127
Study 10906303 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after conservative treatment
Number of subjects: 127
Study 10906303 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-screened)
Number of subjects: 127
Study 8811148 — intervention group
Group type: EXPERIMENTAL
Intervention: Backrest elevation at 0 degrees
Number of subjects: 39
Study 8811148 — intervention group
Group type: EXPERIMENTAL
Intervention: Backrest elevation at 30 degrees
Number of subjects: 39
Study 8811148 — intervention group
Group type: EXPERIMENTAL
Intervention: Backrest elevation at 45 degrees
Number of subjects: 39
Study 8811148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation and vasoactive drugs
Number of subjects: 39
Study 1420754 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 3 g/day
Number of subjects: 108
Study 1420754 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 6 g/day
Number of subjects: 108
Study 1420754 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide (both doses)
Number of subjects: 108
Study 4059802 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide
Number of subjects: 10
Study 4059802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29985668 — intervention group
Group type: EXPERIMENTAL
Intervention: Estonia‐specific optimized speech stimuli for Nasometer II
Number of subjects: 106
Study 29985668 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 106
Study 27983774 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheter (IPC)
Number of subjects: 0
Study 27983774 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 0
Study 25998922 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR‐linked mailings (automated)
Number of subjects: 0
Study 25998922 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated plus telephone assistance (assisted)
Number of subjects: 0
Study 25998922 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated and assisted plus nurse navigation (navigated)
Number of subjects: 0
Study 25998922 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24565347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 50 μg
Number of subjects: 123
Study 24565347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100 μg
Number of subjects: 123
Study 24565347 — intervention group
Group type: COMPARATOR
Intervention: Both groups (50 μg and 100 μg)
Number of subjects: 123
Study 22029878 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated services delivery (ISD) network
Number of subjects: 100
Study 22029878 — intervention group
Group type: COMPARATOR
Intervention: No integrated services delivery (ISD) network
Number of subjects: 100
Study 19235523 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal learning setting with role switching and role definition
Number of subjects: 72
Study 19235523 — intervention group
Group type: COMPARATOR
Intervention: Reciprocal learning settings without role switching and role definition
Number of subjects: 72
Study 16751657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 10 mg per day for 2-7 days (Group A)
Number of subjects: 280
Study 16751657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg per day for 1 day (Group B)
Number of subjects: 280
Study 16751657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg per day for 2 days (Group C)
Number of subjects: 280
Study 16751657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg per day for 1 day and Vitamin K1 10 mg per day for 2-7 days (Group D)
Number of subjects: 280
Study 16751657 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 280
Study 15632893 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (aggressive lipid lowering)
Number of subjects: 893
Study 15632893 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day (moderate lipid lowering)
Number of subjects: 893
Study 11287512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided PTC (12 procedures)
Number of subjects: 19
Study 11287512 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopically guided PTC (12 procedures)
Number of subjects: 19
Study 9390367 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyesys videokeratoscope (windows workstation: version 2000 W)
Number of subjects: 20
Study 9390367 — intervention group
Group type: COMPARATOR
Intervention: Topcon Autokeratometer (KR 3500)
Number of subjects: 20
Study 15374306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramiracetam (600 mg twice a day)
Number of subjects: 24
Study 15374306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3266276 — intervention group
Group type: EXPERIMENTAL
Intervention: Above- and below-lesion EMG control of functional electrical stimulation (FES)
Number of subjects: 0
Study 3266276 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-lesion response-EMG
Number of subjects: 0
Study 3266276 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-lesion EMG
Number of subjects: 0
Study 3266276 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-lesion EMG
Number of subjects: 0
Study 30273282 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garments (CG)
Number of subjects: 10
Study 31667790 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg subcutaneous dose
Number of subjects: 225
Study 31667790 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 75 mg subcutaneous dose
Number of subjects: 225
Study 31667790 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (both doses)
Number of subjects: 225
Study 29924331 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma selenium concentrations (second tertile)
Number of subjects: 1727
Study 29924331 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma selenium concentrations (third tertile)
Number of subjects: 1727
Study 29924331 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of plasma selenium and highest category of intake of β‐cryptoxanthin
Number of subjects: 1727
Study 29924331 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of plasma selenium and highest category of intake of lycopene
Number of subjects: 1727
Study 27581470 — intervention group
Group type: COMPARATOR
Intervention: Bar15/0LS (mean ± SEM), 169 ± 14
Number of subjects: 12
Study 27581470 — intervention group
Group type: COMPARATOR
Intervention: Control2, 164 ± 20
Number of subjects: 12
Study 27581470 — intervention group
Group type: COMPARATOR
Intervention: Bar15/0, 144 ± 15
Number of subjects: 12
Study 27581470 — intervention group
Group type: COMPARATOR
Intervention: Control1, 140 ± 17
Number of subjects: 12
Study 27581470 — intervention group
Group type: COMPARATOR
Intervention: Bar10/5, 117 ± 12
Number of subjects: 12
Study 27581470 — intervention group
Group type: COMPARATOR
Intervention: Bar15/5, 116 ± 9
Number of subjects: 12
Study 27581470 — intervention group
Group type: COMPARATOR
Intervention: Bar10/10, 100 ± 9
Number of subjects: 12
Study 27581470 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein content
Number of subjects: 12
Study 27581470 — intervention group
Group type: EXPERIMENTAL
Intervention: All 5 RS-containing bars
Number of subjects: 12
Study 25177815 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium administered at a dose of 1000 mg/ml intravenously in addition to controlled physical training (CPT) with intensity 80% for 2 weeks (10 SFI)
Number of subjects: 35
Study 25177815 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium group
Number of subjects: 35
Study 22920930 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg daily)
Number of subjects: 9326
Study 22920930 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 9326
Study 22920930 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (5 mg daily)
Number of subjects: 9326
Study 20921542 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of moderate caloric restriction with 8.5 hours of nighttime sleep opportunity
Number of subjects: 10
Study 20921542 — intervention group
Group type: COMPARATOR
Intervention: 14 days of moderate caloric restriction with 5.5 hours of nighttime sleep opportunity
Number of subjects: 10
Study 18754820 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ketamine
Number of subjects: 63
Study 18754820 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mcg/kg fentanyl
Number of subjects: 63
Study 16129547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg four times with 4h intervals)
Number of subjects: 64
Study 16129547 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion (starting from 2 mIU/min, increasing every 30 min with 2 mIU/min increments up to 40 mIU/min)
Number of subjects: 64
Study 16129547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 64
Study 16129547 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 64
Study 12828699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail-splinting technique with splint removal after 3 days (Group 1)
Number of subjects: 57
Study 12828699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail-splinting technique with splint removal after 2 weeks (Group 2)
Number of subjects: 57
Study 12828699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail-splinting technique (both groups)
Number of subjects: 57
Study 11069379 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine injection
Number of subjects: 28
Study 11069379 — intervention group
Group type: COMPARATOR
Intervention: Needle puncture alone
Number of subjects: 28
Study 11069379 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal spermatic vein measurement
Number of subjects: 28
Study 8804093 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification task (reporting orientation of the oblique line)
Number of subjects: 0
Study 8804093 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy localisation task (indicating left or right side of the display)
Number of subjects: 0
Study 8804093 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult localisation task (indicating upper or lower part of the display)
Number of subjects: 0
Study 8804093 — intervention group
Group type: EXPERIMENTAL
Intervention: Left vs right localisation
Number of subjects: 0
Study 8804093 — intervention group
Group type: EXPERIMENTAL
Intervention: Up vs down localisation
Number of subjects: 0
Study 1299504 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/day chromium picolinate (CrPic)
Number of subjects: 59
Study 1299504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 59
Study 6432374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged physical exercise with calorie deficiency and sleep deprivation
Number of subjects: 24
Study 6432374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged physical exercise with calorie deficiency
Number of subjects: 24
Study 6432374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged physical exercise and calorie deficiency
Number of subjects: 24
Study 6432374 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 24
Study 30565407 — intervention group
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin Lispro (BCLIS)
Number of subjects: 43
Study 30565407 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (ASP)
Number of subjects: 43
Study 30565407 — intervention group
Group type: COMPARATOR
Intervention: Faster insulin aspart (FIA)
Number of subjects: 43
Study 29770541 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 50 mg qd
Number of subjects: 53
Study 29770541 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide 2.5 mg per day
Number of subjects: 53
Study 27015624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg with 100 mL normal saline)
Number of subjects: 90
Study 27015624 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1 g intravenously)
Number of subjects: 90
Study 27015624 — intervention group
Group type: COMPARATOR
Intervention: Dexketoprofen (50 mg intravenously)
Number of subjects: 90
Study 24224787 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led self-management programme (six 2-hour sessions)
Number of subjects: 242
Study 22205604 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PALs)
Number of subjects: 85
Study 22205604 — intervention group
Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Number of subjects: 85
Study 22205604 — intervention group
Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs) after PALs
Number of subjects: 85
Study 21257441 — intervention group
Group type: EXPERIMENTAL
Intervention: Monepantel, administered orally at a minimum dose of 2.5 mg/kg bodyweight
Number of subjects: 0
Study 21257441 — intervention group
Group type: COMPARATOR
Intervention: Untreated control sheep
Number of subjects: 0
Study 18498921 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg q8h i.v. (4-hour infusion)
Number of subjects: 0
Study 18498921 — intervention group
Group type: COMPARATOR
Intervention: Imipenem 500 mg q6h (30-minute infusion) or 1000 mg q8h i.v. (1-hour infusion)
Number of subjects: 0
Study 16122453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive domain summary scores based on precedence
Number of subjects: 204
Study 16122453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive domain summary scores based on principal components analysis
Number of subjects: 204
Study 16122453 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 204
Study 12686280 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hours time in bed
Number of subjects: 66
Study 12686280 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 hours time in bed
Number of subjects: 66
Study 12686280 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 hours time in bed
Number of subjects: 66
Study 12686280 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 hours time in bed
Number of subjects: 66
Study 10584839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.3 mg/day
Number of subjects: 30
Study 10584839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fludrocortisone)
Number of subjects: 30
Study 8965976 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 2 x 200 mg daily
Number of subjects: 60
Study 8965976 — intervention group
Group type: COMPARATOR
Intervention: Sodium Valproate (VPA) 2 x 300 mg daily
Number of subjects: 60
Study 1871175 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) for 10 days
Number of subjects: 0
Study 1871175 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil (SFO) for 10 days
Number of subjects: 0
Study 1871175 — intervention group
Group type: COMPARATOR
Intervention: Paraffin for 10 days
Number of subjects: 0
Study 2998219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose fentanyl anaesthesia (0.01 mg/kg bw) - Group A
Number of subjects: 32
Study 2998219 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fentanyl anaesthesia (0.035 mg/kg bw) - Group B
Number of subjects: 32
Study 30817438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with adrenaline
Number of subjects: 9
Study 30817438 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 29987324 — intervention group
Group type: COMPARATOR
Intervention: EHR‐alone group
Number of subjects: 794
Study 29987324 — intervention group
Group type: COMPARATOR
Intervention: EHR plus education group
Number of subjects: 794
Study 29987324 — intervention group
Group type: COMPARATOR
Intervention: EHR tools alone and EHR plus education interventions
Number of subjects: 794
Study 27211040 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbead array (MBA) assay with a cut-off of 500
Number of subjects: 133
Study 27211040 — intervention group
Group type: COMPARATOR
Intervention: Hemagglutination inhibition assay (HAI)
Number of subjects: 133
Study 27211040 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbead array (MBA) assay with a cut-off of 500 for A/Brisbane strain
Number of subjects: 133
Study 27211040 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbead array (MBA) assay with a cut-off of 500 for B/Florida strain
Number of subjects: 133
Study 27211040 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results from both studies
Number of subjects: 133
Study 24880194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided axillary nerve block (ANB) combined with suprascapular nerve block (SSNB) using 10 mL ropivacaine
Number of subjects: 42
Study 24880194 — intervention group
Group type: COMPARATOR
Intervention: Suprascapular nerve block (SSNB) with 10 mL 0.75% ropivacaine and axillary nerve block (ANB) with 10 mL saline
Number of subjects: 42
Study 22414839 — intervention group
Group type: EXPERIMENTAL
Intervention: SpiraPost (group A; DMG, Englewood, NJ)
Number of subjects: 40
Study 22414839 — intervention group
Group type: COMPARATOR
Intervention: DT Light‐Post Illusion X‐RO (group B; Bisco Inc, Schaumburg, IL)
Number of subjects: 40